dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agentes para la dermatitis, excluidos los corticosteroides - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
dupixent solución inyectable 200 mg/1,14 ml (dupilumab )
sanofi-aventis de chile s.a. - dupilumab - sin formulas
dupixent solución inyectable 300 mg/2 ml (dupilumab)
sanofi-aventis de chile s.a. - dupilumab - sin formulas
imfinzi
astrazeneca ab - durvalumab - carcinoma, pulmón no microcítico - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
imfinzi concentrado para solución para perfusión 120 mg/2,4 ml (durvalumab)
astrazeneca s.a. - durvalumab - sin formulas
imfinzi concentrado para solución para perfusión 500 mg/10 ml (durvalumab)
astrazeneca s.a. - durvalumab - sin formulas
dupixent® 300mg/2ml solucion inyectable
sanofi - aventis del peru s.a. - droguerÍa - dupilumab - solucion inyectable - 300 mg/2 ml - por jeringa precargada 2.00 ml - - dupilumab
dupixent® 200mg/1.14ml solucion inyectable
sanofi - aventis del peru s.a. - droguerÍa - dupilumab - solucion inyectable - 200 mg/1.14 ml - por jeringa precargada 1.14 ml - - dupilumab
imfinzi® 50 mg/ml concentrado para solución para perfusión
astrazeneca peru s.a. - droguerÍa - durvalumab - concentrado para solución para perfusión - 50 mg/ml - por mililitro 1.00 - - durvalumab
imfinzi ®
astrazeneca ab suecia - durvalumab 50mg/ml - concentrado para solucion para perfusion - durvalumab 50mg/ml